Q32 Bio (QTTB) Return on Capital Employed (2018 - 2026)
Q32 Bio (QTTB) posted quarterly Return on Capital Employed of 41.13% for Q1 2026, up 13039.0% year-over-year from N/an in Q1 2025, and up 17.84% quarter-over-quarter from 34.9% in Q4 2025.
Q32 Bio (QTTB) Return on Capital Employed (2018 - 2026) Analysis & Trends
Q32 Bio's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 41.13% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 13039.0% year-over-year to 41.13%; the TTM figure through Mar 2026 stood at 41.13% (up 13039.0% YoY), while the FY2025 annual figure was 25.72%, up 14991.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 41.13%, up from 34.9% in the prior quarter.
- The five-year high for Return on Capital Employed was 41.13% in Q1 2026, with the low at 89.65% in Q2 2025.
- The 5-year median for Return on Capital Employed is 55.07% (2022), against an average of 53.45%.
- The sharpest annual moves came in 2025 and 2026: Return on Capital Employed slumped 3483 bps in 2025, then surged 13039 bps in 2026.
- Q32 Bio's Return on Capital Employed stood at 59.77% in 2022, then fell by 2 bps to 60.74% in 2023, then tumbled by 33 bps to 80.64% in 2024, then soared by 143 bps to 34.9% in 2025, then climbed by 18 bps to 41.13% in 2026.
- Business Quant data shows QTTB's Return on Capital Employed at 41.13% in Q1 2026, 34.9% in Q4 2025, and 85.57% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Q32 Bio | 359.61 Mn | 253.31 Mn | - | 25.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.44% |
| Mar 31, 2026 | 41.13% |
| Dec 31, 2025 | 34.90% |
| Sep 30, 2025 | -85.57% |
| Jun 30, 2025 | -89.65% |
| Mar 31, 2025 | -89.26% |
| Dec 31, 2024 | -80.64% |
| Sep 30, 2024 | -77.39% |
| Jun 30, 2024 | -54.82% |
| Mar 31, 2024 | -83.49% |
| Dec 31, 2023 | -60.74% |
| Sep 30, 2023 | -44.00% |
| Jun 30, 2023 | -51.04% |
| Mar 31, 2023 | -52.93% |
| Dec 31, 2022 | -59.77% |
| Sep 30, 2022 | -53.31% |
| Jun 30, 2022 | -47.00% |
| Mar 31, 2022 | -55.07% |
| Dec 31, 2021 | -47.02% |
| Sep 30, 2021 | -40.73% |